Floatz logo

Ampreloxetine

Multiple System Atrophy

Theravance BiopharmaSmall moleculePhase 3Dormant
CCC
51/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
36/ 100
Competitive Position
95/ 100

Competitive context

27 Active assets in the Multiple System Atrophy cohort.

Asset / SponsorPhaseRating
Droxidopa
Loma Linda University
Phase 3BB
Zoledronate
California Pacific Medical Center Research Institute
Phase 4BB
Ath-434
Alterity Therapeutics
Phase 2B
Ioflupane
GE Healthcare
Phase 3B
Riluzole
King's College London
Phase 3B

View all 39 →

Same molecule, other indications

Ampreloxetine is also rated in:

primary orthostatic hypotensionDormant
CCC
Indicative · Phase 3
54 / 100
View asset →
pure autonomic failureDormant
CCC
Indicative · Phase 3
51 / 100
View asset →
Parkinson diseaseDormant
CC
Indicative · Phase 3
46 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →